Compare Mercadolibre Inc (MELI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Organon & Co. Common Stock — how do they compare? Mercadolibre Inc trades at $1,828.03 (market cap $95.11B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Mercadolibre Inc is far larger — about 26.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Organon & Co. Common Stock for 0 Days on average.
| MELI | OGN | |
|---|---|---|
Market Cap | $95.11B | $3.62B |
Volume | 242,115 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $13.81 |
52-Week Low | $1.55K | $5.70 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $102.76B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,839.11, down 2.82% on the day, amid a bullish technical setup and strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $28.89 billion, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while its fintech credit portfolio surged 75% in Q2 2026.
Outlook remains positive given dominant Latin American e-commerce and fintech positioning, but risks include macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Wall Street consensus is strongly bullish with a $2,160 price target, though profit trends warrant monitoring for sustained shareholder returns.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
